VCAM1 and melanoma: In this context it is interesting to note that the therapeutic reduction of cell-cell adhesion by inhibition of VLA-4 (α4β1 integrin; ligand of endothelial VCAM-1) in multiple sclerosis patients may elevate the risk to develop melanoma (e.g. [25]).